For instance, in NSCLC with STK11/KEAP1 mutations resistant to PD-(L)1 inhibitors, adding CTLA-4 blockade may restore responses, implying compensatory CTLA-4 upregulation [45]. Here, STK11 is linked to non-small cell lung carcinoma.